Sol-Gel Technologies (SLGL) has released an update.
Sol-Gel Technologies Ltd., an innovative dermatology company, announced a management realignment with CEO Dr. Alon Seri-Levy stepping down by the end of 2024 and Eyal Ben-Or being appointed as the new CFO. Under Dr. Seri-Levy’s tenure, the company launched FDA-approved products EPSOLAY® and TWYNEO® and completed a successful U.S. IPO. The company is also conducting a Phase 3 clinical trial for SGT-610, a treatment for Gorlin syndrome.
For further insights into SLGL stock, check out TipRanks’ Stock Analysis page.
